Nathalie Corva News Today : Breaking News, Live Updates & Top Stories | Vimarsana
MaaT Pharma Reports Cash and Revenues for Third Quarter 2022
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
MaaT Pharma Reports Cash and Revenues for Third Quarter 2022
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
South-Korean biotech Y-Biologics and French mid-pharma Pierre Fabre enter into a worldwide exclusive license agreement in the highly innovative field of immuno-oncology
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
South-Korean biotech Y-Biologics and French mid-pharma Pierre Fabre [ ]
cataniaoggi.it - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cataniaoggi.it Daily Mail and Mail on Sunday newspapers.
(0)
BESTHESDA, Maryland and CASTRES, France, April 8, 2021 /PRNewswire/ The US biopharmaceutical company ValenzaBio and the French pharmaceutical group Pierre Fabre announced today the signing of a license agreement of a preclinical insulin-like growth factor-1 receptor (IGF-1R) antagonist antibody, for the treatment of Thyroid Eye Disease (TED), an endocrine disease with unmet medical need. ValenzaBio received from Pierre Fabre the worldwide and exclusive rights to develop and commercialize, outside of oncology, the anti-IGF-1R antibody, discovered by Pierre Fabre at its Center of immunology located in Saint-Julien-en-Genevois (France), with the aim of treating patients suffering from TED. Other indications in rare diseases could also be developed by ValenzaBio. In parallel, Pierre Fabre is pursuing the development of its anti-IGF-1R ADC program (W0101) in oncology.